New insider activity at United Therapeutics ( (UTHR) ) has taken place on December 10, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Nilda Mesa recently sold 187 shares of United Therapeutics stock, amounting to a total transaction value of $90,064.
Recent Updates on UTHR stock
In the last 24 hours, United Therapeutics has seen several analysts raise their price targets for the company’s stock, driven by significant developments and positive market sentiment. UBS increased its price target to $600, citing advancements in United Therapeutics’ clinical xenotransplantation efforts within the EXPAND study, which marks a pioneering step in the field. RBC Capital raised its target to $587, reflecting optimism about the company’s innovative approaches and potential market impact. H.C. Wainwright and Morgan Stanley also adjusted their targets upwards to $525 and $447, respectively, acknowledging the company’s strategic advancements and robust pipeline that could enhance its market position.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ strong financial performance and positive earnings call are the most significant factors contributing to the score. The company’s robust revenue growth, profitability, and strategic initiatives provide a solid foundation for future growth. Technical analysis supports a bullish trend, although valuation metrics suggest the stock is fairly valued. The absence of a dividend yield indicates a focus on reinvestment for growth. Potential risks include market competition and regulatory uncertainties.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 32.24%
Average Trading Volume: 620,991
Technical Sentiment Signal: Buy
Current Market Cap: $20.65B